GENENTECH PULMOZYME SALES ARE $111.3 MIL. IN 1995, MARKET PENETRATION AT 60%, COMPANY REPORTS; PFIZER NORVASC 4TH QUARTER SALES GROWTH IS 73%
Executive Summary
Genentech's cystic fibrosis therapy Pulmozyme (dornase alfa) is being used by 60% of CF patients over the age of five, Genentech CEO Arthur Levinson, PhD, told the Hambrecht & Quist health care conference Jan. 10 in San Francisco.